Emergent BioSolutions | EBS - Equity Capital And Reserves


Emergent BioSolutions reported $649.3M in Equity Capital and Reserves for its fiscal quarter ending in December of 2023.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amarin USD 443.62M 5.8M Jun/2026
ANI Pharmaceuticals USD 562.3M 21.58M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Exelixis USD 1.94B 225.57M Mar/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
Lonza CHF 9.13B 513M Dec/2025
Merck USD 45.88B 6.73B Mar/2026
Moderna USD 6.76B 647M Jun/2026
Myriad Genetics USD 303.9M 33.5M Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Pacira USD 671.98M 18.08M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025